Table 1 Comparison of characteristics between subjects with and without CKD (n = 3,268)
| Â | CKD (+) | CKD (-) | P |
|---|---|---|---|
| Â | (n = 564) | (n = 2,704) | Â |
CKD stage 3 (eGFR < 60 ml/min/1.73m2) | 561 (99.5%) | - | - |
    Stage 4 (eGFR < 30) | 0 (0%) | - | |
    Stage 5 (eGFR < 15) | 3 (0.5%) | - | |
eGFR (ml/min/1.73m2) | 53.7 ± 6.0 | 78.3 ± 12.5 | < 0.001 |
Age (years) | 60.4 ± 7.2 | 55.9 ± 8.7 | < 0.001 |
Male | 260 (46.1%) | 1,327 (49.1%) | 0.198 |
Body mass index | 23.5 ± 3.1 | 23.4 ± 3.3 | 0.413 |
Systolic blood pressure (mm Hg) | 130.1 ± 19.8 | 128.1 ± 19.4 | 0.029 |
Diastolic blood pressure (mm Hg) | 78.8 ± 12.4 | 78.6 ± 11.9 | 0.746 |
Use of anti-hypertensive drugs | 149 (26.4%) | 486 (18.0%) | < 0.001 |
Fasting plasma glucose (mg/dL) | 98.8 ± 22.1 | 100.0 ± 20.8 | 0.291 |
HbA1c (%) | 5.22 ± 0.70 | 5.22 ± 0.66 | 0.942 |
Use of glucose-lowering drugs | 31 (5.5%) | 110 (4.1%) | 0.129 |
Total cholesterol (mg/dL) | 218.2 ± 34.0 | 211.1 ± 33.9 | < 0.001 |
HDL cholesterol (mg/dL) | 62.0 ± 15.9 | 63.3 ± 16.3 | 0.071 |
Triglyceride (mg/dL)* | 106 (76.5-151) | 104 (74-154) | 0.992 |
Use of lipid-lowering drugs | 70 (12.4%) | 225 (8.3%) | 0.002 |
Uric acid (mg/dL) | 5.53 ± 1.47 | 5.10 ± 1.33 | < 0.001 |
History of cardiovascular diseases | 34 (6.0%) | 80 (3.0%) | <0.001 |
History of cerebrovascular diseases | 29 (5.1%) | 52 (1.9%) | < 0.001 |
Current smokers | 69 (12.2%) | 484 (17.9%) | 0.001 |
Current drinkers | 295 (52.3%) | 1,510 (55.8%) | 0.138 |